KPTI has been the topic of a number of other reports. Wedbush lifted their price target on shares of Karyopharm Therapeutics from $15.00 to $18.00 in a report on Wednesday, November 6th. ValuEngine cut shares of Karyopharm Therapeutics from a buy rating to a hold rating in a research note on Tuesday, December 3rd. Robert W. Baird set a $25.00 price objective on shares of Karyopharm Therapeutics and gave the company a buy rating in a report on Tuesday, September 24th. Zacks Investment Research upgraded Karyopharm Therapeutics from a hold rating to a buy rating and set a $17.00 price objective for the company in a research report on Wednesday, November 13th. Finally, HC Wainwright lifted their target price on Karyopharm Therapeutics from $32.00 to $36.00 and gave the stock a buy rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $19.86.
KPTI stock traded down $0.32 during midday trading on Tuesday, hitting $16.69. The company’s stock had a trading volume of 11,918 shares, compared to its average volume of 1,143,735. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -5.34 and a beta of 2.60. The company has a quick ratio of 7.16, a current ratio of 7.16 and a debt-to-equity ratio of 2.03. Karyopharm Therapeutics has a 12 month low of $3.92 and a 12 month high of $18.70. The company has a 50 day moving average of $14.99 and a two-hundred day moving average of $10.08.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Monday, November 4th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.17. Karyopharm Therapeutics had a negative net margin of 909.24% and a negative return on equity of 187.25%. The firm had revenue of $13.15 million for the quarter, compared to the consensus estimate of $1.61 million. On average, analysts anticipate that Karyopharm Therapeutics will post -3.13 earnings per share for the current fiscal year.
In related news, insider Sharon Shacham sold 20,000 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $12.00, for a total value of $240,000.00. Also, EVP Christopher Brett Primiano sold 13,000 shares of Karyopharm Therapeutics stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $17.45, for a total value of $226,850.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 133,342 shares of company stock valued at $1,942,371. 13.26% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of Montreal Can purchased a new stake in Karyopharm Therapeutics during the second quarter valued at approximately $29,000. Tower Research Capital LLC TRC raised its holdings in Karyopharm Therapeutics by 536.6% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,476 shares of the company’s stock valued at $34,000 after buying an additional 2,930 shares during the period. Envestnet Asset Management Inc. boosted its stake in Karyopharm Therapeutics by 12.4% during the second quarter. Envestnet Asset Management Inc. now owns 11,980 shares of the company’s stock worth $72,000 after buying an additional 1,319 shares during the period. Virtu Financial LLC purchased a new position in Karyopharm Therapeutics during the third quarter worth $99,000. Finally, Commonwealth Equity Services LLC bought a new position in Karyopharm Therapeutics during the third quarter valued at $124,000. 93.14% of the stock is currently owned by institutional investors.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).
Featured Story: What is the Euro STOXX 50 Index?
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.